CYTR - サイトレックス (CytRx Corporation) サイトレックス

 CYTRのチャート


 CYTRの企業情報

symbol CYTR
会社名 CytRx Corp (サイトレックス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 サイトレックス(CytRx Corporation)はバイオ医薬品の研究開発会社であり、主に腫瘍学に従事する。同社の腫瘍学薬品パイプラインには、がん適応症向けの「INNO-206」、「tamibarotene」及び「bafetinib」の3つの臨床開発プログラムが含まれる。「INNO-206」は、腫瘍標的ドキソルビシン抱合体である。平成23年5月13日、同社は前臨床および臨床データ、知的財産権、およびそれらの化合物に関連するその他資産を全部Orphazyme ApSに売却した。平成23年12月期決算期において、同社はSynthRxにおける19%の持分をADVENTRX Pharmaceuticalsに売却した。   サイトレックスは米国のバイオ医薬品研究開発会社。主にがんや腫瘍に焦点を当てる。同社は、軟部組織肉腫用の希少疾患用医薬品として広く使われている抗がん剤ドキソルビシンの改良版であるアルドキソルビシンの臨床開発に従事。アルドキソルビジンは徐放性で、腫瘍を選択しながら標的にすることにより、悪性腫瘍を減少させる。本社はロサンゼルス。   CytRx Corp. is a biopharmaceutical research and development company, which engages in the discovery, research, and clinical development of novel anti-cancer drug candidates. It focuses on developing the Linker Activated Drug Release (LADR) technology platform, a discovery engine to help create a pipeline of anti-cancer molecules that will avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor. The company was founded on February 28, 1985 and is headquartered in Los Angeles, CA.
本社所在地 11726 San Vicente Blvd. Suite 650 Los Angeles CA 90049 USA
代表者氏名 Steven A. Kriegsman スティーブンA.クリエンスマン
代表者役職名 Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者
電話番号 +1 310-826-5648
設立年月日 31079
市場名 NASDAQ Small Cap
ipoyear 1986年
従業員数 17人
url www.cytrx.com
nasdaq_url https://www.nasdaq.com/symbol/cytr
adr_tso
EBITDA EBITDA(百万ドル) -19.69115
終値(lastsale) 1.03
時価総額(marketcap) 34646626.03
時価総額 時価総額(百万ドル) 34.98300
売上高 売上高(百万ドル) 0.10000
企業価値(EV) 企業価値(EV)(百万ドル) 7.93732
当期純利益 当期純利益(百万ドル) -16.66919
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 CytRx Corporation revenues was not reported. Net loss decreased 72% to $7.1M. Lower net loss reflects Research_Development Expense decrease of 84% to $2M (expense) Gain (loss) on warrant derivative liabil increase from $4.3M (expense) to $527K (income) General and administrative decrease of 35% to $3.3M (expense).

 CYTRのテクニカル分析


 CYTRのニュース

   The Daily Biotech Pulse: ASCO Presentations From Roche, Celgene & More, Edwards Recommends Rejection Of Mini-tender Offer  2019/06/04 11:45:58 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 3) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Array Biopharma Inc (NASDAQ: ARRY ) Ascendis Pharma A/S (NASDAQ: ASND ) Mirati Therapeutics Inc (NASDAQ: MRTX )(reacted to ASCO presentation on a rival drug by Amgen, Inc. (NASDAQ: AMGN )) Misonix, Inc. (NASDAQ: MSON )(received FDA approval for its ultrasonic surgical platform) Trevi Therapeutics Inc (NASDAQ: TRVI ) (analyst began covering the stock after the IPO quiet period expiry ) Down In The Dumps (Biotech stocks hitting 52-week lows on June 3) Arcus Biosciences Inc (NYSE: RCUS ) Abeona Therapeutics Inc (NASDAQ: ABEO ) Aduro BioTech Inc (NASDAQ: ADRO )(reacted to ASCO presentation on its Phase 1b data for ADU-S100) Akers Biosciences Inc (NASDAQ: AKER ) Aldeyra Therapeutics Inc (NASDAQ: ALDX ) BIOLINERX LTD/S ADR (NASDAQ: BLRX ) Celldex Therapeutics, Inc. (NASDAQ: CLDX )(reacted to ASCO presentation on CDX-3379) Cerus Corporation (NASDAQ: CERS ) ContraVir Pharmaceuticals (NASDAQ: CTRV )(began trading on a reverse split-adjusted basis) Cyclerion Therapeutics Inc (NASDAQ: CYCN ) CytRx Corporation (NASDAQ: CYTR ) Dynavax Technologies Corporation (NASDAQ: DVAX ) Evogene Ltd …
   CytRx beats by $0.02  2019/05/15 13:31:00 Seeking Alpha
   CytRx Corporation Highlights Patent Issued for Use of Aldoxorubicin in the Treatment of Brain Cancer  2019/05/08 13:00:00 Yahoo Finance
"We are continually impressed with the progress that our partner and licensee NantCell has made with advancing aldoxorubicin in high unmet need oncology indications," said Eric Curtis, CytRx's President and Chief Operating Officer.
   CytRx beats by $0.12, revenue in-line  2019/03/29 13:26:02 Seeking Alpha
CytRx (CYTR): FY GAAP EPS of -$0.29 beats by $0.12. Revenue of $0.25M (+150.0% Y/Y) in-line. Press Release
   The Daily Biotech Pulse: ASCO Presentations From Roche, Celgene & More, Edwards Recommends Rejection Of Mini-tender Offer  2019/06/04 11:45:58 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 3) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Array Biopharma Inc (NASDAQ: ARRY ) Ascendis Pharma A/S (NASDAQ: ASND ) Mirati Therapeutics Inc (NASDAQ: MRTX )(reacted to ASCO presentation on a rival drug by Amgen, Inc. (NASDAQ: AMGN )) Misonix, Inc. (NASDAQ: MSON )(received FDA approval for its ultrasonic surgical platform) Trevi Therapeutics Inc (NASDAQ: TRVI ) (analyst began covering the stock after the IPO quiet period expiry ) Down In The Dumps (Biotech stocks hitting 52-week lows on June 3) Arcus Biosciences Inc (NYSE: RCUS ) Abeona Therapeutics Inc (NASDAQ: ABEO ) Aduro BioTech Inc (NASDAQ: ADRO )(reacted to ASCO presentation on its Phase 1b data for ADU-S100) Akers Biosciences Inc (NASDAQ: AKER ) Aldeyra Therapeutics Inc (NASDAQ: ALDX ) BIOLINERX LTD/S ADR (NASDAQ: BLRX ) Celldex Therapeutics, Inc. (NASDAQ: CLDX )(reacted to ASCO presentation on CDX-3379) Cerus Corporation (NASDAQ: CERS ) ContraVir Pharmaceuticals (NASDAQ: CTRV )(began trading on a reverse split-adjusted basis) Cyclerion Therapeutics Inc (NASDAQ: CYCN ) CytRx Corporation (NASDAQ: CYTR ) Dynavax Technologies Corporation (NASDAQ: DVAX ) Evogene Ltd …
   CytRx beats by $0.02  2019/05/15 13:31:00 Seeking Alpha
   CytRx Corporation Highlights Patent Issued for Use of Aldoxorubicin in the Treatment of Brain Cancer  2019/05/08 13:00:00 Yahoo Finance
"We are continually impressed with the progress that our partner and licensee NantCell has made with advancing aldoxorubicin in high unmet need oncology indications," said Eric Curtis, CytRx's President and Chief Operating Officer.
   CytRx beats by $0.12, revenue in-line  2019/03/29 13:26:02 Seeking Alpha
CytRx (CYTR): FY GAAP EPS of -$0.29 beats by $0.12. Revenue of $0.25M (+150.0% Y/Y) in-line. Press Release
   The Daily Biotech Pulse: ASCO Presentations From Roche, Celgene & More, Edwards Recommends Rejection Of Mini-tender Offer  2019/06/04 11:45:58 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 3) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Array Biopharma Inc (NASDAQ: ARRY ) Ascendis Pharma A/S (NASDAQ: ASND ) Mirati Therapeutics Inc (NASDAQ: MRTX )(reacted to ASCO presentation on a rival drug by Amgen, Inc. (NASDAQ: AMGN )) Misonix, Inc. (NASDAQ: MSON )(received FDA approval for its ultrasonic surgical platform) Trevi Therapeutics Inc (NASDAQ: TRVI ) (analyst began covering the stock after the IPO quiet period expiry ) Down In The Dumps (Biotech stocks hitting 52-week lows on June 3) Arcus Biosciences Inc (NYSE: RCUS ) Abeona Therapeutics Inc (NASDAQ: ABEO ) Aduro BioTech Inc (NASDAQ: ADRO )(reacted to ASCO presentation on its Phase 1b data for ADU-S100) Akers Biosciences Inc (NASDAQ: AKER ) Aldeyra Therapeutics Inc (NASDAQ: ALDX ) BIOLINERX LTD/S ADR (NASDAQ: BLRX ) Celldex Therapeutics, Inc. (NASDAQ: CLDX )(reacted to ASCO presentation on CDX-3379) Cerus Corporation (NASDAQ: CERS ) ContraVir Pharmaceuticals (NASDAQ: CTRV )(began trading on a reverse split-adjusted basis) Cyclerion Therapeutics Inc (NASDAQ: CYCN ) CytRx Corporation (NASDAQ: CYTR ) Dynavax Technologies Corporation (NASDAQ: DVAX ) Evogene Ltd …
   CytRx beats by $0.02  2019/05/15 13:31:00 Seeking Alpha
   CytRx Corporation Highlights Patent Issued for Use of Aldoxorubicin in the Treatment of Brain Cancer  2019/05/08 13:00:00 Yahoo Finance
"We are continually impressed with the progress that our partner and licensee NantCell has made with advancing aldoxorubicin in high unmet need oncology indications," said Eric Curtis, CytRx's President and Chief Operating Officer.
   CytRx beats by $0.12, revenue in-line  2019/03/29 13:26:02 Seeking Alpha
CytRx (CYTR): FY GAAP EPS of -$0.29 beats by $0.12. Revenue of $0.25M (+150.0% Y/Y) in-line. Press Release

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 サイトレックス CYTR CytRx Corporation)

 twitter  (公式ツイッターやCEOツイッターなど)